Literature DB >> 15826939

The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases.

K Vinod Vijayan1, Yan Liu, Wensheng Sun, Masaaki Ito, Paul F Bray.   

Abstract

Integrin beta(3) is polymorphic at residue 33 (Leu(33) or Pro(33)), and the Pro(33)-positive platelets display enhanced aggregation, P-selectin secretion, and shorter bleeding times. Because outside-in signaling is critical for platelet function, we hypothesized that the Pro(33) variant provides a more efficient signaling than the Leu(33) isoform. When compared with Pro(33)-negative platelets, Pro(33)-positive platelets demonstrated significantly greater serine/threonine phosphorylation of extracellular signal-regulated kinase (ERK2) and myosin light chain (MLC) but not cytoplasmic phospholipase A2 upon thrombin-induced aggregation. Tyrosine phosphorylation of integrin beta(3) and the adaptor protein Shc was no different in the fibrinogen-engaged platelets from both genotypes. The addition of Integrilin (alpha(IIb)beta(3)-fibrinogen blocker) or okadaic acid (serine/threonine phosphatase inhibitor) dramatically enhanced ERK2 and MLC phosphorylation in the Pro(33)-negative platelets when compared with Pro(33)-positive platelets, suggesting that integrin engagement during platelet aggregation activates serine/threonine phosphatases. The phosphatase activity of myosin phosphatase (MP) that dephosphorylates MLC is inactivated by phosphorylation of the myosin binding subunit of MP at Thr(696), and aggregating Pro(33)-positive platelets exhibited an increased Thr(696) phosphorylation of MP. These studies highlight a role for the dephosphorylation events via the serine/threonine phosphatases during the integrin outside-in signaling mechanism, and the Leu(33) --> Pro polymorphism regulates this process. Furthermore, these findings support a mechanism whereby the reported enhanced alpha granule secretion in the Pro(33)-positive platelets could be mediated by an increased phosphorylation of MLC, which in turn is caused by an increased phosphorylation and subsequent inactivation of myosin phosphatase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826939     DOI: 10.1074/jbc.M500872200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.

Authors:  Ana M Coutinho; Inês Sousa; Madalena Martins; Catarina Correia; Teresa Morgadinho; Celeste Bento; Carla Marques; Assunção Ataíde; Teresa S Miguel; Jason H Moore; Guiomar Oliveira; Astrid M Vicente
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

2.  Beta3 integrin haplotype influences gene regulation and plasma von Willebrand factor activity.

Authors:  Katie E Payne; Paul F Bray; Peter J Grant; Angela M Carter
Journal:  Atherosclerosis       Date:  2007-11-28       Impact factor: 5.162

Review 3.  The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.

Authors:  Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

4.  The human platelet antigen-1b (Pro33) variant of αIIbβ3 allosterically shifts the dynamic conformational equilibrium of this integrin toward the active state.

Authors:  Giulia Pagani; Joana P V Pereira; Volker R Stoldt; Andreas Beck; Rüdiger E Scharf; Holger Gohlke
Journal:  J Biol Chem       Date:  2018-02-09       Impact factor: 5.157

5.  Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway.

Authors:  Panagiotis Flevaris; Zhenyu Li; Guoying Zhang; Yi Zheng; Junling Liu; Xiaoping Du
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

6.  Mechanism of activation and functional role of protein kinase Ceta in human platelets.

Authors:  Yamini S Bynagari; Bela Nagy; Florin Tuluc; Kamala Bhavaraju; Soochong Kim; K Vinod Vijayan; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

7.  Applying a targeted label-free approach using LC-MS AMT tags to evaluate changes in protein phosphorylation following phosphatase inhibition.

Authors:  Feng Yang; Navdeep Jaitly; Hemalatha Jayachandran; Quanzhou Luo; Matthew E Monroe; Xiuxia Du; Marina A Gritsenko; Rui Zhang; David J Anderson; Samuel O Purvine; Joshua N Adkins; Ronald J Moore; Heather M Mottaz; Shi-Jian Ding; Mary S Lipton; David G Camp; Harold R Udseth; Richard D Smith; Sandra Rossie
Journal:  J Proteome Res       Date:  2007-10-12       Impact factor: 4.466

8.  Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans.

Authors:  Ana Marin D Carneiro; Edwin H Cook; Dennis L Murphy; Randy D Blakely
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Structure of an extended β3 integrin.

Authors:  Dongwen Zhou; Aye Myat Myat Thinn; Yan Zhao; Zhengli Wang; Jieqing Zhu
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

10.  Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.

Authors:  Kendra H Oliver; Tammy Jessen; Emily L Crawford; Chang Y Chung; James S Sutcliffe; Ana M Carneiro
Journal:  Mol Pharmacol       Date:  2014-04-02       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.